APIs and ADCs: a journey through high potency
Drug development based on potent compounds can be quite challenging. Crossing the boundary from small molecule to biologics into antibody-drug conjugate (ADC) territory adds levels of complexity. Learn more about infrastructure requirements and best practices. Live: Friday, Sept. 27, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Sept. 27, 2020 Register free
Register free: http://www.pharmtech.com/pt_w/potency
Event Overview:
Drug development based on potent compounds can be quite challenging. Crossing the boundary from small molecule to biologics into antibody-drug conjugate (ADC) territory adds levels of complexity.
In this webcast, experts will elaborate on best practices and infrastructure requirements that facilitate accelerated timelines to clinic.
Topics include:
- The advantages of seamless integration of highly potent APIs, monoclonal antibodies, and ADC operations
- The impact of supporting integrated service offerings on expansion strategies
- ADC process scale-up from clinical manufacturing to commercial drug substance production
- A case study will review the development, rapid scaling, and commercial production of HPAPI drug substance
Speakers: Maurits Janssen, PhD, Senior Director Head of Commercial Development, API, Lonza Pharma & Biotech
Bernhard Stump, PhD, Head of Process Development Bioconjugates, Lonza Pharma & Biotech
Time and date: Friday, Sept. 27, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after airing until Sept. 27, 2020
Sponsor: Lonza Pharma & Biotech
Register free: http://www.pharmtech.com/pt_w/potency
